Coronavirus, the EU Parliament calls for the temporary revocation of vaccine patents
Pfizer / BioNtech, in September request for free vaccines for the age group 2-11
Share
June 14, 2021 - US biotech firm Novavax has announced that its vaccine is over 90% effective against Covid-19, including its variants. test results show that the new vaccine provides powerful protection against the coronavirus and also against variants. In the study involving 29,960 people, the vaccine demonstrated an overall effectiveness of 90.4 percent, exactly like Pfizer-BioNTech and Moderna products, and superior to Johnson & Johnson's single-dose vaccine. Vaccine maker Novavax plans to seek authorization for its Covid-19 vaccine in the United States, Europe and elsewhere by the end of September. By that date, the company expects to be able to produce up to 100 million doses per month.
Our vaccine, Novavax continues, uses a different technology from those used for vaccines already widely authorized in the world, based on proteins that trigger an immune response, without viruses. Novavax's is a protein-based vaccine - as the European Drug Agency EMA describes it - that contains tiny particles obtained from a laboratory-made version of the Spike protein found on the surface of the pandemic coronavirus. It also uses an adjuvant, a substance that helps strengthen immune responses stimulated by the injection-shield.
The "Prevent-19 trial confirms that NVX-CoV2373 offers a reassuring safety and tolerability profile - says Gregory M. Glenn, President of Research & Development, Novavax - These data show high levels of efficacy and reaffirm the vaccine's ability to prevent Covid- 19 in a phase in which the genetic evolution of the virus is underway. Our vaccine will contribute in a fundamental way to the solution of the Covid emergency ", is convinced Glenn who thanks" the participants in the study, the operators who made it possible in this way like our supporters, including the US government. "
The easy-to-store and transport Novavax vaccine is expected to play an important role in increasing vaccine supplies to developing countries. "Many of our first doses will go to low- and middle-income countries, and that was the initial goal," Novavax chief executive Stanley Erck told The Associated Press. The Novavax study involved nearly 30,000 people aged 18 and over in the United States and Mexico. Two-thirds received two doses of the vaccine, three weeks apart, and the rest received sham injections. 77 cases of Covid-19 were detected: 14 in the group that received the vaccine and the rest in volunteers who received the placebo. No one in the immunized group had moderate or severe disease,compared with 14 in the placebo group. The vaccine was equally effective against several variants, including the one first detected in the UK which is dominant in the US and high-risk populations, including the elderly and people with other health problems. Side effects were mostly mild, such as pain at the injection site. There have been no reports of unusual blood clots or heart problems, Erck said.There have been no reports of unusual blood clots or heart problems, Erck said.There have been no reports of unusual blood clots or heart problems, Erck said.